Skip to main content
Premium Trial:

Request an Annual Quote

Gene Security Network Raises $20M, Renames Itself Natera

NEW YORK (GenomeWeb News) – Gene Security Network today announced it has completed a $20 million financing round and changed its name to Natera.

The funds will go toward development and commercialization of the company's non-invasive prenatal diagnostic test for Down syndrome and other genetic ailments. A clinical trial funded by the National Institutes of Health for the prenatal test also will be expanded with a launch of the test anticipated sometime this year.

Its test uses bioinformatics technology to deliver results from quantities of DNA as small as that from a single cell, it said.

Lightspeed Venture Partners led the round and were joined by existing investors Claremont Creek Ventures and Sequoia Capital.

Natera, based in Redwood City, Calif., raised $4 million in a Series A round in 2007 and $6 million and $12 million in subsequent rounds.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.